Certain Shares of Stayble Therapeutics AB are subject to a Lock-Up Agreement Ending on 22-AUG-2023.
Details:
A number of members of the Board of Directors and management of the Company have together, through a so-called lock-up agreement, with Sedermera Corporate Finance AB as counterpart, undertaken, with customary exceptions, not to sell any existing shareholdings or such shareholdings that are received through subscription in the Rights Issue during a period of six months from the announcement of the Rights Issue. Existing shareholdings under lock-up corresponds to approximately 3.42 percent of the total number of shares before the Rights Issue.